No Data
As of July 19, 2024, Kaien Technology (688687.SH) had a total of 7630 shareholders.
On July 22, Gelunhui reported that, according to the interactive platform for investors, as of July 19, 2024, Kein Technology (688687.SH) had 7,630 shareholders.
Kain Technology (688687.SH): has not yet entered the field of thrombocytosis.
On July 17, Gelun Hui reported that Kaiyin Technology (688687.SH) announced on the investor interaction platform that the company has conducted three clinical trials for different indications with Pai Yi Sheng: treatment of low-replication chronic HBV infection, shingles, and hepatic epithelioid hemangioendothelioma indications. Currently, all projects are steadily moving forward according to plan, and there is no layout of the thrombocytosis field. Please pay attention to public information for follow-up research and development of this product.
As of July 10th, 2024, there were 8047 shareholders in Kaien Technology (688687.SH) company.
On July 11th, Gelonhui reported that as of July 10th, 2024, there were 8,047 shareholders of CAIN Technology (688687.SH) according to the company's investor platform.
As of June 28, 2024, the number of shareholders in Kaien Technology (688687.SH) was 7,078.
Kaiyin Technology (688687.SH) stated on the investor interaction platform on July 3 that as of June 28, 2024, the number of shareholders in the company is 7,078.
As of June 7th, 2024, there were 6,984 shareholders in Kain Technology (688687.SH).
On June 12th, Gelunhui reported that as of June 7th, 2024, the number of shareholders in Kayin Technology (688687.SH) was 6,984 on the investor interaction platform.
Kain Technology (688687.SH) will distribute 2.5 yuan for every 10 shares in 2023. The stock registration date is May 21
Zhitong Finance App News, Kain Technology (688687.SH) announced that the company will implement the 2023 equity distribution and distribute a cash dividend of 2.5 yuan (tax included) for every 10 shares to all shareholders. The share registration date is May 21.
No Data
